Last reviewed · How we verify

Propofol based general anesthesia

The First Affiliated Hospital of Anhui Medical University · FDA-approved active Small molecule

Propofol is a sedative-hypnotic agent that enhances inhibitory GABA neurotransmission in the central nervous system to produce rapid unconsciousness and anesthesia.

Propofol is a sedative-hypnotic agent that enhances inhibitory GABA neurotransmission in the central nervous system to produce rapid unconsciousness and anesthesia. Used for Induction and maintenance of general anesthesia, Sedation in mechanically ventilated patients in intensive care units.

At a glance

Generic namePropofol based general anesthesia
Also known asControl
SponsorThe First Affiliated Hospital of Anhui Medical University
Drug classSedative-hypnotic; GABA-A receptor positive allosteric modulator
TargetGABA-A receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Propofol acts as a positive allosteric modulator of GABA-A receptors, increasing chloride ion influx and neuronal hyperpolarization. This results in depression of the central nervous system, producing sedation, hypnosis, and anesthesia. It has rapid onset and offset due to its lipophilic properties and quick redistribution from the brain.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: